Wall Street brokerages expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report earnings of $0.67 per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Neurocrine Biosciences’ earnings. The highest EPS estimate is $0.79 and the lowest is $0.42. Neurocrine Biosciences posted earnings per share of $0.52 during the same quarter last year, which would suggest a positive year over year growth rate of 28.8%. The company is expected to issue its next quarterly earnings report on Monday, November 4th.
According to Zacks, analysts expect that Neurocrine Biosciences will report full-year earnings of $0.80 per share for the current fiscal year, with EPS estimates ranging from $0.40 to $0.98. For the next year, analysts expect that the firm will post earnings of $3.36 per share, with EPS estimates ranging from $1.94 to $4.68. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, July 29th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.13. Neurocrine Biosciences had a return on equity of 0.46% and a net margin of 2.98%. The business had revenue of $183.58 million for the quarter, compared to analyst estimates of $161.79 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. Neurocrine Biosciences’s revenue was up 89.5% on a year-over-year basis.
In other news, insider Haig P. Bozigian sold 19,297 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $85.02, for a total value of $1,640,630.94. Following the transaction, the insider now owns 161,273 shares of the company’s stock, valued at $13,711,430.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Haig P. Bozigian sold 17,268 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $82.62, for a total value of $1,426,682.16. Following the completion of the transaction, the insider now directly owns 157,812 shares in the company, valued at approximately $13,038,427.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 211,897 shares of company stock worth $19,536,555. Company insiders own 4.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of NBIX. Evolution Wealth Advisors LLC acquired a new position in shares of Neurocrine Biosciences in the second quarter valued at approximately $40,000. Capital Investment Advisory Services LLC acquired a new position in shares of Neurocrine Biosciences in the second quarter valued at approximately $43,000. NEXT Financial Group Inc grew its position in shares of Neurocrine Biosciences by 89.8% in the second quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock valued at $47,000 after purchasing an additional 265 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Neurocrine Biosciences by 70.5% in the second quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock valued at $51,000 after purchasing an additional 246 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its position in shares of Neurocrine Biosciences by 9,242.9% in the first quarter. Quadrant Capital Group LLC now owns 654 shares of the company’s stock valued at $56,000 after purchasing an additional 647 shares during the last quarter. 94.45% of the stock is currently owned by institutional investors.
NBIX opened at $97.59 on Friday. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $126.98. The firm has a market capitalization of $8.91 billion, a PE ratio of 443.59, a PEG ratio of 5.06 and a beta of 1.32. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.44. The business’s 50-day simple moving average is $91.19 and its 200 day simple moving average is $84.60.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Featured Article: Special Dividends
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.